Jefferies (NYSE:JEF) analyst Eun Yang maintained a Buy rating on United Therapeutics (NASDAQ:UTHR) on Thursday, setting a price target of $235, which is approximately 19.98% above the present share price of $195.86.
Yang expects United Therapeutics to post earnings per share (EPS) of $3.62 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in United Therapeutics, with an average price target of $250.33.
The analysts price targets range from a high of $276 to a low of $235.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $444.7 million and a net profit of $228.7 million. The company's market cap is $8.82 billion.
According to TipRanks.com, Jefferies analyst Eun Yang is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 6.2% and a 49.14% success rate.
United Therapeutics Corp . operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.